The independent platform for news, articles and advice for professionals in laboratory medicine

Good Laboratory Practice (GLP) hERG screening service launched

Metrion Biosciences, the specialist ion channel contract research and drug discovery company based in Cambridge, UK (pictured), has received notification from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) that it is now a member of the UK GLP (Good Laboratory Practice) Compliance Monitoring Programme, and is therefore able to offer GLP-compliant hERG ion channel screening services to the global life sciences community.

GLP hERG screening is a vital step in the transition from preclinical research to Phase 1 clinical trials in humans, regardless of therapeutic target class. Pharmacological assessments against the human ether-à-go-go related gene (hERG) potassium channel, conducted in compliance with GLP principles and adhering to ICH S7A and ICH S7B guidelines, is an important step in the Investigational New Drug (IND) application process for potential small molecule therapeutics.

Metrion has offered hERG profiling services since the company was founded in 2015 and has since expanded its cardiac safety offer to include a full panel of comprehensive in vitro proarrhythmia assay (CiPA) services. Addition of the new GLP hERG service further strengthens the company’s suite of cardiac safety screening assays, providing a substantial range of options to assess potential cardiac liabilities as preclinical discovery research programmes are progressed.

Metrion’s expanding portfolio of ion channel services now includes the new GLP hERG assays in addition to high-throughput screening (HTS) in both automated electrophysiology and fluorescence formats, a comprehensive ion channel cell biology capability, translational assays, and significant expertise for neuroscience drug discovery research.

Upcoming Events

POCT Innovators: The Power to Disrupt Series

Cloth Hall Court, Leeds. UK
20 March, 2024

Interpreting Reports: UK NEQAS Haematology

ONLINE
21st March 2024

USCAP 113th Annual Meeting

Baltimore Convention Center, Baltimore, Maryland, USA
23-28 March, 2024

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

POCT Innovators: The Power to Disrupt Series

Cloth Hall Court, Leeds. UK
20 March, 2024

Interpreting Reports: UK NEQAS Haematology

ONLINE
21st March 2024

USCAP 113th Annual Meeting

Baltimore Convention Center, Baltimore, Maryland, USA
23-28 March, 2024

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999
www.step-communications.com
© 2024 Step Communications Ltd. Registered in England. Registration Number 3893025